The US Food and Drug Administration (FDA) has granted Orphan Drug designation to Curis’ blood cancer candidate. The cancer biotech company announced today that the agency granted Orphan Drug designation to its lead proprietary drug candidate, CUDC-907, for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). The agency grants orphan …